HYPERTRIGLYCERIDEMIA IN CHRONIC KIDNEY DISEASE - A CLINICALLY RELEVANT STUDY
|
|
- Wesley Cook
- 5 years ago
- Views:
Transcription
1 IJCRR Vol 06 issue 13 Section: Healthcare Category: Research Received on: 04/04/14 Revised on: 02/05/14 Accepted on: 28/05/14 HYPERTRIGLYCERIDEMIA IN CHRONIC KIDNEY DISEASE - A CLINICALLY RELEVANT STUDY, Takkallapalli Anitha Dept of Anatomy, Chalmeda Anandrao Institute of Medical Sciences, Bommakal, Karimnagar, AP, India of Corresponding Author: tanita.205@gmail.com ABSTRACT Background: Cardiovascular disease is the major cause of mortality and morbidity in patients with chronic kidney disease [CKD] Hypertriglyceridemia may contribute to the progression of atherosclerosis and it is considered to be an independent risk factor for patients of chronic kidney disease. Aim: To study the effects of hypertriglyceridemia, especially in males and females suffering from chronic kidney disease, to comparative evaluation of serum triglyceride levels in patients of chronic kidney disease undergoing hamodialysis and patients on conservative therapy. Methodology: Our study included 100 patients of chronic kidney disease, of which 66 were males and 34 were females. Results: On decade wise grouping, we found maximum number of patients of chronic kidney disease between years (42.8%) followed by years (40%). The most common cause of chronic kidney disease was found to be type II diabetes mellitus (38%), followed by hypertension (32%) and hypertension 18%. The mean triglyceride levels in both males and females were less than 150 mg/dl in 40% of patients followed by borderline high in 32% and very high in 28% of chronic kidney disease patients. The mean serum triglycerides in patients on conservative therapy was 151.2±35.31 and in patients undergoing haemodialysis, the mean serum triglycerides was ± Conclusion: Our study shows that patients of chronic kidney disease have elevated serum triglycerides, in patients on Haemodialysis there is hypertriglyceridemia which could contribute to atherosclerosis and cardiovascular disease. Keywords: Chronic kidney disease [CKD], Maintenance haemodialysis, [MHD] Serum triglycerides. INTRODUCTION Chronic renal failure is the permanent and significant reduction in glomerular filtration rate, or chronic irreversible destruction of kidney tissue [1]. Cardiovascular disease is the leading cause of death in chronic kidney disease patients. Both traditional and non-traditional factors play a role in increased cardiovascular mortality. Among traditional risk factors, diabetes, hypertension and dyslipidemia are the leading causes. Anemia, inflammation, oxidative stress, disorders of calcium and phosphorus metabolism, arterial stiffness and malnutrition can be stated as nontraditional risk factors [2]. Chronic renal failure is often associated with dyslipoproteinemia, high levels of cholesterol and triglycerides, as well as decrease in the polyunsaturated fatty acids. Each of these abnormalities has been identified as an independent risk factor for atherosclerosis [3]. Hypertriglyceridemia is a common phenomenon in chronic renal failure and is associated with endothelial dysfunction. Plasma triglycerides, but Page 64
2 not cholesterol, is increased in most patients with advanced renal failure. A high triglyceride concentration predicts coronary heart disease independently from other known factors [4]. Cardiovascular disease begins in the early stages of renal disease. Therefore it is imperative to screen all patients of chronic kidney disease for dyslipidemias and treat them intensively before they develop End stage renal disease. MATERIALS AND METHODS The present study was conducted in patients admitted to the department of nephrology, at the chalmeda Anand Rao Institute of Medical Sciences, Bommakal, Karimnagar during the period of Inclusion Criteria:-Patients of chronic kidney disease, who have previous normal lipid profile. Diagnostic Criteria of chronic kidney disease: 1) Clinical sings and symptoms of Uremia 2) Patients with serum creatinine >1.5 mg/dl 3) Bilateral shrunken kidney / loss of cortico medullary differentiation on ultrasonography of abdomen. Exclusion Criteria:-patients of dyslipidemia due to other causes like hypothyroidism, ethanol, liver disease, known dyslipidemic diabetic patients, HIV patients, patients with genetic disorders were excluded from the study. METHOD Informed consent was obtained from all the 100 patients including 66 males and 34 females. All selected patients were subjected to detailed history and complete physical examination. The data collected was noted serially in a predesigned proforma. After 12 hours of fasting, blood samples of patients on conservative therapy as well as patients undergoing haemodialysis were collected and sent for serum triglyceride analysis. OBSERVATIONS The following criteria have been taken into consideration for interpretation of the results. 1) Age and sex of chronic kidney disease patients 2) Aetiology of chronic kidney disease 3) Evaluation of serum triglycerides in males and females 4) Treatment modalities of chronic kidney disease patients and estimation of their serum triglycerides. Table 1 - Age and Sex distribution Age Group Total No.of cases % Male % Female % < > Total Page 65
3 Aetiology Table 2 - Aetiology of chronic kidney disease Total No.of % Male % Female % cases Type2DM HTN Chronic Glomerulonephritis Obstructive uropathy Chronic Pyelonephritis Idiopathic Total Table 3 -- Difference in serum Triglycerides S. Triglycerides (mg/dl) Male MeanTG±SD Female MeanTG±SD Total % < ± ± Borderline high ± ± High> ± ± Very High> Total Table 4 - Treatment modalities of chronic kidney disease patients and their mean serum triglycerides Serum trigly Treatment No.of % Male % Female % Mean±SD patients Conservative therapy Haemodialysis ± ±69.72 RESULTS In our study, 100 patients of chronic kidney disease were included of which 66 were males and 34 were females. On decade wise grouping we found maximum number of patients between years (42%) followed by years (20%). The mean age of total number of patients was The mean age for male patients was 49.60±16.43 and the mean age for female patients was 4.47±10.26 (table no.1). The most common cause of chronic kidney disease was found to be type II DM [38%] followed by hypertension Page 66
4 [32%] (table no.2). The mean triglyceride levels in both males and females were less than 150mg/dl in 40% patients, followed by borderline high in 32% and very high in 28% of chronic kidney disease patients. Mean total triglyceride level was found to be 175.9± In males it is 170.2±47.85 and females it is ±73.40 (table no.3) The mean serum triglyceride levels in patients undergoing haemodialysis was found to be higher i.e 205.8±69.72 than the patients on conservative therapy i.e 151.2±35.31 DISCUSSION Patients with chronic kidney disease are at an increased risk of cardiovascular (CVD) disease and have higher prevalence of hyperlipidemia than the general population [5]. The risk of cardiovascular disease varies on the type of lipid abnormalities, the target population, the cause of renal disease and the degree of reduction on glomerular filtration rate [6]. The present study was conducted in 100 chronic kidney disease patients. The mean age of male patients was and for females patients was years. The overall male to female ratio was 1.94:1. Feast YG and smith SR [7] analysed age, sex and racial difference, and the incidence of renal disease in american population and found lowest incidence in children(10 years) and highest in the elderly (>40 years). In our study, the maximum numbers of patients is between years and males are more commonly affected than females (table no.1). Wing Aj [8] studied causes of chronic kidney disease in different parts of the world and found that geographical variation occurs in different parts of the world. According to United States Renal Data System 1999, the most common cause of chronic kidney disease is Diabetes mellitus (33.2%), followed by hypertension (24%). In the present study, the leading cause of chronic kidney disease was diabetes mellitus (38%) followed by hypertension (32%) [table no.2]. Moreover, the concentration of triglycerides rises with increasing albumin excretion rate in parients with type 1 diabetes. In addition, there is increase in Low Density Lipoprotein mass and atherogenic small dense Low Density Lipoprotein particles, which correlates with the plasma triglyceride concentrations [9]. In the patients of diabetes and hypertension with chronic kidney disease, micro albuminuria is predictive of future proteinuria, progressive decline in renal function, accelerated atherosclerosis and increased cardiovascular mortality [10]. The hypertriglyceridemia is the most common plasma lipid abnormality in patients with renal failure and it is considered as an important risk factor for atherosclerotic vascular disease [11]. Shah [12] showed that significant hypertriglyceridemia does develop in a majority of chronic kidney disease patients. Anderson [13] suggested that when lipoprotein pattern in chronic kidney disease was analysed, hypertriglyceridemia was found in 43% of patients. In the present study 60% of patients presented with elevated serum triglycerides [table no.3]. Progressive renal failure, especially that associated with proteinuria, is accompanied by abnormalities of lipoprotein transport. Typically, the dyslipidemia is reflected predominantly in increased serum levels of triglycerides with high levels of very low density lipoprotein, apo B and pre-b high density lipoprotein, and low levels of high density lipoprotein and of apo A [14]. Impaired clearance of chylomicrons and very low density lipoprotein has emerged as the dominant factor for the increased serum triglyceride concentration. Lipoprotein lipase (LPL) is the rate limiting step in lipolysis of chylomicrons and very low density lipoprotein. Lipoprotein lipase binds to heparin sulfate proteoglycans on the cell surface of endothelium. In proteinuric renal diseases a down regulation of Lipoprotein lipase protein abundance and enzymatic activity was found [14]. Experimental data support the notion that triglyceride rich lipoproteins of lower densities are Page 67
5 atherogenic and thrombogenic due to abnormal receptor mediated interactions with fibroblasts, macrophages and endothelial cells. It also has been suggested that the increased levels of Lipoprotein (a) in chronic kidney disease patients could represent a risk factor for atherogenesis in these patients. In their study, Cressman [15] have provided evidence that in haemodialysis patients, elevated Lipoprotein (a) is an independent risk factor for clinical events attributed to coronary artery disease. In our study, the serum triglycerides were found to be significantly higher in Haemodialysis patients as compared to the patients on conservative therapy. Similar hypertriglyceridemia was also observed in several other studies including the CHOICE study [12, 16] Furthermore, Hahn et al [17] have found that dialyzed patients with cardiovascular disease have a 50% increase in the triglyceride levels in comparison with unaffected individuals on dialysis. The recent K/DOQ guidelines on the management of dyslipidaemias suggest the following: 1) For those chronic kidney disease patients with triglycerides 200mg/dl and non-high density lipoprotein cholesterol 130mg/dl, the aim is to achieve non- high density lipoprotein cholesterol < 130 mg/dl. Initial treatment comprises lifestyle changes plus a low-dose statin which is increased as required [18]. 2) In patients with high fasting triglycerides 500mg-dl, the initial goal of treatment is to prevent acute pancreatitis. The target is to achieve triglyceride level < 500mg/dl and suggested treatment is with therapeutic lifestyle changes which includes diet, weight reduction, increased physical activity and abstinence from alcohol followed by a fibrate or niacin [18]. CONCLUSION Patients of dyslipidemias will require lifestyle modification and lipid lowering therapy. All patients with hypertriglyceridemia considered as high risk should be screened and treated accordingly. ACKNOWLEDGMENT Authors acknowledge the immense help received from the scholars whose articles are cited and included in references of this manuscript. The authors are also grateful to author / editors / publishers of all those articles, journals and books from where the literature for this article has been reviewed and discussed. REFERENCES 1. Dewardener, H.E, An outline of normal and abnormal function. In: The kidney 4 th edition. Churchill Livingstone New York 1986; Munter P, He J, Astor BC, Folsom AR, Coresh J. Traditional and non-traditional risk factors predict coronary heart disease:results from atherosclerosis risk in communities study J.Am. soc Nephrol.2005;16[2]: Assman G, Schulte H, Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Munster study. Am J cardio. 1992;70: Castelli;wp. The triglyceride issue: a view from fremingh am, Am Heart J 1986:112: Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J kidney Dis. 1998;32:S142-S Weiner DE, Tighiouart H. stark PC, Amin MG, Macleod B, Griffith JL et al. kidney disease as a risk factor for recurrent cardiovascular disease and mortality Am J kidney Dis 2004; 44: Feast TG and smith SR: Incidence of advance CRF and need for end stage renal replacement. BMJ / 1990;301, Page 68
6 8. Wing AJ: Courses on end stage renal failure Oxford textbook of clinical nephrology. Oxford university press: : Marrie M, Bouhanick B, Berrut G: Micro albuminuria. Curr opin nephrol Hypertens 3; , Hillege HL, Fidler V, Diercks GF, Van Gilst WH, dezeecw D, van veldhuisen DJ, Gans RO, Janssen WH, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation, 2002; 106: Green D, stone NJ, Krumlowsky A. Putative atherogenic factors in patients with chronic renal failure. Prog cardiovascular Dis. 1983; 26: [pub Med] 12. Shah B, Nair S, Sirsat RA, Ashavaid TF, Nair KG, Dyslipidemia in patients with chronic renal failure and in renal transplant patients. J. Post grad Med. 1994;40[2]; Anderson AJ : Lipoprotein pattern in chronic renal failure (moyo CLIN proc.1976 oct; 51910); 660-4) 14. Vaziri ND: Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63; , Cress man MD, Heyka RJ, Paganini EP, et al Lipoproterin(a) is an independent risk factor for cardio vascular disease in haemodialysis patients. Circulation 1992; Longenecker JC, coresh J, Powe NR. Traditional cardiovascular disease risk factor on dialysis patients compared with the general population: The CHOICE study.j Am SOC Nephrol 2002; 13(1); Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factor in chronic haemodialysis patients with special attention to hyper lipoproteinemias. Atherosclerosis 1983;48: K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. AM J kidney Dis2003;41(4 SUPPL):I-IV,S1-S91. Page 69
JMSCR Vol 07 Issue 01 Page January 2019
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.66 Lipid Profile in Different Stages
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationChronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza
Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management Fabio Mazza CKD (Chronic Kidney Disease) is an ever-increasing clinical condition marked by a progressive reduction
More informationDyslipidemia in chronic kidney disease excluding diabetic and nephrotic aetiology
International Journal of Advances in Medicine Velayudham R et al. Int J Adv Med. 2017 Dec;4(6):1586-1590 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20175172
More informationStudy of Lipid Profile in Patients with Chronic Kidney Disease on Conservative Management and Hemodialysis
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/22 Study of Lipid Profile in Patients with Chronic Kidney Disease on Conservative Management and Hemodialysis K Rajani
More informationINTERNATIONAL JOURNAL OF BIOASSAYS ISSN: X CODEN: IJBNHY OPEN ACCESS
ORIGINAL RESEARCH ARTICLE A CLINICAL STUDY OF DYSLIPIDEMIA IN PATIENTS OF CHRONIC KIDNEY DISEASE Gourav Garg 1, Sumit Pal Singh Chawla 2 * and Sarabjot Kaur 2 1 Department of Medicine, Government Medical
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More information2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries
Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global
More informationIntroduction. 1. Introduction
1. Introduction Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal kidney function, and a progressive decline in glomerular filtration
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationHypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC
Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationJOSHUA K. KAYIMA INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY
INTERLINKING CARDIOVASCULAR DISEASE, CHRONIC KIDNEY DISEASE, AND OBESITY JOSHUA K. KAYIMA ASSOCIATE PROFESSOR DEPT. OF CLINICAL MEDICINE AND THERAPEUTICS UNIVERSITY OF NAIROBI Introduction According to
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationHypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002
Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationA STUDY ON DYSLIPIDAEMIA IN CHRONIC KIDNEY DISEASE (CKD) WITH SPECIAL REFERENCE TO HAEMODIALYSIS
A STUDY ON DYSLIPIDAEMIA IN CHRONIC KIDNEY DISEASE (CKD) WITH SPECIAL REFERENCE TO HAEMODIALYSIS Shweta Sharma 1, Sandhya Gautam 2, Dhanveer Singh 3, Prachi Sharma 4, Avriti Baweja 5 1Assistant Professor,
More informationChapter (5) Etiology of Low HDL- Cholesterol
Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the
More informationIndian Journal of Basic and Applied Medical Research; March 2018: Vol.-7, Issue- 2, P
Original article Evaluation of alteration of various lipid parametersincluding Apolipoprotein A1 and Apolipoprotein B in chronic kidney disease (CKD) patients in a tertiary care centre in Eastern India
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationyear resident, Department of Medicine, B. J. Medical college, Ahmedabad.
Clinical Study of Type 2 Diabetes Mellitus Patients with or without Cerebrovascular Feature and Its Correlation with Other Comorbidity / Diabetic Complication Vivek Sidhapura 1*, Bipin Amin 2, Amit Potulwar
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationZuhier Awan, MD, PhD, FRCPC
Metabolism, Atherogenic Properties and Agents to Reduce Triglyceride-Rich Lipoproteins (TRL) The Fifth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 8-11, 2019 Zuhier
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationChronic Kidney Disease with Special Reference to Dyslipidemia
IJHRMLP, Vol: 02 No: 02, July, 2016 Printed in India 2014 IJHRMLP, Assam, India ORIGINAL PAPER Chronic Kidney Disease with Special Reference to Dyslipidemia (Page 18-23) Chronic Kidney Disease with Special
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More information1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?
1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationΟ ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη
Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη Κωνσταντίνος Τζιόμαλος Επίκουρος Καθηγητής Παθολογίας Α Προπαιδευτική Παθολογική Κλινική, Νοσοκομείο
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. 5. Classification of chronic kidney disease based on evaluation of kidney function
5. Classification of chronic kidney disease based on evaluation of kidney function Date written: April 2005 Final submission: May 2005 GUIDELINES No recommendations possible based on Level I or II evidence
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationA comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus
Original Research Article A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Deepa Kalikavil Puthenveedu 1, Sundaraj
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS
LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationUniversity of Groningen. C-reactive protein and albuminuria Stuveling, Erik Marcel
University of Groningen C-reactive protein and albuminuria Stuveling, Erik Marcel IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationA Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/21 A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Bingi Srinivas
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationRole of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal
More informationManaging Chronic Kidney Disease: Reducing Risk for CKD Progression
Managing Chronic Kidney Disease: Reducing Risk for CKD Progression Arasu Gopinath, MD Clinical Nephrologist, Medical Director, Jordan Landing Dialysis Center Objectives: Identify the most important risks
More informationJMSCR Vol 06 Issue 04 Page April 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i4.162 Research Article A Study of
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationElevation of Serum Creatinine: When to Screen, When to Refer. Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC
Elevation of Serum Creatinine: When to Screen, When to Refer Bruce F. Culleton, MD, FRCPC; and Jolanta Karpinski, MD, FRCPC Presented at the University of Calgary s CME and Professional Development 2006-2007
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Diabetic Dyslipidemia Insulin Resistance May Be One of the Causes of Mahendra D. Bikkad, Suresh
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationNephrology Unit- CHU Liège- Ulg- Belgium
Are the complications of arteriovenous fistulas associated with an abnormal Ankle-Brachial Index in Hemodialysis? A 4y study P. Xhignesse, A. Saint-Remy, B. Dubois, JC. Philips, JM. Krzesinski Nephrology
More informationLab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.
Patient Education Lab Values Explained Common Tests to Help Diagnose Kidney Disease Lab work, urine samples and other tests may be given as you undergo diagnosis and treatment for renal failure. The test
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationProtecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
More informationPATTERN OF LIPID PROFILE IN CHRONIC RENAL FAILURE PATIENT WITH GFR < 60 ML/MIN/1.73 M 2 ON CONSERVATIVE TREATMENT VERSUS MAINTENANCE HAEMODIALYSIS
PATTERN OF LIPID PROFILE IN CHRONIC RENAL FAILURE PATIENT WITH GFR < 60 ML/MIN/1.73 M 2 ON CONSERVATIVE TREATMENT VERSUS MAINTENANCE HAEMODIALYSIS MD. DAHARUL ISLAM 1, MOHAMMAD RAFIQUL ISLAM 2, S M TAJDIT
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy
Control of Hypercholesterolaemia and Progression of Diabetic Nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. All hypercholesterolaemic diabetics
More informationCKDinform: A PCP s Guide to CKD Detection and Delaying Progression
CKDinform: A PCP s Guide to CKD Detection and Delaying Progression Learning Objectives Describe suitable screening tools, such as GFR and ACR, for proper utilization in clinical practice related to the
More information13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:
CARDIOVASCULAR DISEASES (CVD) and NUTRITION Major cause of morbidity & mortality in Canada & other developed countries e.g., majority of approved health claims on food labels relate to lowering CVD Relation
More informationPediatric Dyslipidemia: Angela Gooden MSN, RN, CPNP- AC/PC, Texas Children s Hospital, Pediatric Cardiology
Pediatric Dyslipidemia: Angela Gooden MSN, RN, CPNPAC/PC, Texas Children s Hospital, Pediatric Cardiology Objectives Define pediatric dyslipidemia Describe the association between pediatric dyslipidemia
More informationKidney Failure- Are you at risk?? ( 腎功能衰竭 - 你是在高危險群嗎?)
Kidney Failure- Are you at risk?? ( 腎功能衰竭 - 你是在高危險群嗎?) Dr Goh Heong Keong, Penang www.passpaces.com/kidney.htm Outline of Lecture Introduction( 介紹 ) Definition of Chronic kidney disease( 慢性肾脏病的定义 ) Stages
More informationDyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan
Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationHigh density lipoprotein metabolism
High density lipoprotein metabolism Lipoprotein classes and atherosclerosis Chylomicrons, VLDL, and their catabolic remnants Pro-atherogenic LDL HDL Anti-atherogenic Plasma lipid transport Liver VLDL FC
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationISSN X (Print) Original Research Article. DOI: /sjams *Corresponding author Dr. D.V.Andure
DOI: 10.21276/sjams.2016.4.7.1 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(7A):2312-2317 Scholars Academic and Scientific Publisher (An International Publisher
More informationMetabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD
Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy
More informationMicroalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients:
ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 1 Microalbuminuria As Predictor Of Severity Of Coronary Artery Disease In Non-Diabetic Patients: F Aziz, S Penupolu, S Doddi, A Alok, S Pervaiz,
More informationSERUM LIPID PROFILES DURING ONSET AND REMISSION OF STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDREN: A PROSPECTIVE CASE CONTROL STUDY
Indian J.L.Sci. 5 (2) : 27-31, 2016 SERUM LIPID PROFILES DURING ONSET AND REMISSION OF STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDREN: A PROSPECTIVE CASE CONTROL STUDY a1 b c SRINIVASA MURTHY C L, RAHIMTAJ
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationArteriosclerosis & Atherosclerosis
Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationChronic Kidney Disease - An Overview
REVIEW ARTICLE KERALA MEDICAL JOURNAL Chronic Kidney Disease - An Overview Rajesh R Nair Department of Nephrology, Amrita Institute of Medical Sciences, Kochi, Kerala* ABSTRACT Published on 28 th December
More informationA study of lipid profile in non-diabetic chronic kidney disease
International Journal of Advances in Medicine Ganta V et al. Int J Adv Med. 2016 Nov;3(4):965-970 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20163732
More informationMICROALBUMINURIA - MORE THAN A RENAL FUNCTION INDICATOR FOR HYPERTENSIVE PATIENTS WITH ASSOCIATED CHRONIC DISEASES
Jurnal edical Aradean (Arad edical Journal Vol. XIV, issue -,, pp. - Vasile Goldis University Press (www.jmedar.ro ICROALBUIURIA - ORE THA A REAL FUCTIO IDICATOR FOR HYPERTESIVE PATIETS WITH ASSOCIATED
More informationFibrate and cardiovascular disease: Evident from meta-analysis. Thongchai Pratipanawatr
Fibrate and cardiovascular disease: Evident from meta-analysis Thongchai Pratipanawatr ??? ย คห นใหม ย คห นกลาง ย คห นเก า ?? Statin era? ย คห นใหม ย คห นกลาง ย คห นเก า CURRENT ROLE OF FIBRATE What are
More informationOffice Management of Reduced GFR Practical advice for the management of CKD
Office Management of Reduced GFR Practical advice for the management of CKD CKD Online Education CME for Primary Care April 27, 2016 Monica Beaulieu, MD FRCPC MHA CHAIR PROVINCIAL KIDNEY CARE COMMITTEE
More informationUpdate On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?
Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown
More information(dyslipidemia) (CKD) (hypercholesterolemia) (hypertriglyceridemia) (CVD) B (apolipoprotein(apo)b) (VLDL) (HDL) ( VLDL)
(dyslipidemia) (CKD) (CVD) (CKD) (nephrotic syndrome) (dyslipidemia) (proteinuria) (hypercholesterolemia) (hypertriglyceridemia) B (apolipoprotein(apo)b) (VLDL) (IDL)(LDL) (HDL) ( VLDL) (HDL-C) LDL-C HDL-C
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More information